Introduction
Atherothrombosis (thrombus formation superimposed upon atherosclerosis) is an unpredictable, sudden disruption (rupture or erosion/fi ssure) of an atherosclerotic plaque, which leads to platelet activation and thrombus formation (1). Rupture/fi ssure of a plaque acts as a stimulus for atherothrombosis (2) . From a clinical point of view, atherothrombosis is a progressive, generalized disorder with manifestations -either acute or chronic and oft en multiple in any single patient -aff ecting the coronary, cerebral, and peripheral circulation (3). In the case of a non-occlusive thrombus, ischemic symptoms are temporary and thrombosis can contribute to plaque growth through formation and resolution of subclinical platelet thrombi (thrombus formation is a dynamic process in which platelets aggregate but also spontaneously disaggregate, eventually leading to embolization of platelet aggregates from an evolving thrombus) (4). In the case of an occlusive thrombus, there will be an acute ischemic syndrome in the coronary, cerebral, or peripheral vascular territory depending on the localization of the atherosclerotic plaque, potentially leading to permanent tissue damage. Because of the generalized and progressive nature of atherothrombosis, symptoms of the disease in one vascular bed are highly predictive of the risk of further ischemic events elsewhere. Cardiovascular and cerebrovascular events and peripheral artery disease (PAD) are thus part of a continuum of disease with the common underlying pathophysiology of atherothrombosis (5) .
In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of PAD, producing intermittent claudication (leg pain on walking that is relieved by rest), ischemic necrosis, and, potentially, loss of the limb. PAD aff ects about 8 -10 million Americans, and every year it causes 
Key messages
Th e overall quality of the evidence concerning diagnostic • tools and antithrombotic interventions in PAD is low in most cases. New antithrombotic treatment is a major target to • improve prevention of vascular events in patients with PAD.
Innovative imaging techniques should be explored to • identify PAD subjects at the highest vascular risk.
In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb. PAD with IC is often undiagnosed and, in turn, undertreated. The low percentage of diagnosis ( ∼ 30%) in this setting of PAD is of particular concern because of the potential worsening of PAD (amputation) and the high risk of adverse vascular outcomes (vascular death, coronary artery disease, stroke). A Medline literature search of the highest-quality systematic reviews and meta-analyses of randomized controlled trials documents that, due to risk of bias, imprecision, and indirectness, the overall quality of the evidence concerning diagnostic tools and antithrombotic interventions in PAD is generally low. Areas of research emerge from the information collected. Appropriate treatments for PAD patients will only derive from ad-hoc studies. Innovative imaging techniques are needed to identify PAD subjects at the highest vascular risk. Whether IC unresponsive to physical exercise and smoking cessation identifi es those with a heritable predisposition to more severe vascular events deserves to be addressed. Devising ways to improve prevention of vascular events in patients with PAD implies a co-ordinated approach in vascular medicine.
claudication necessitating surgical repair or amputation. During 5 years of follow-up (16), 10% -20% of patients with IC would be expected to experience non-fatal AMI or stroke. In addition, death from coronary artery disease, other vascular diseases, and non-cardiovascular causes would be expected in 30%. In a longer (10-y) follow-up (17) , about 55% of PAD (ABI Ͻ 0.9) patients died of cardiovascular disease, 10% of cerebrovascular disease, and 25% of non-vascular reasons. Less than 10% died of other vascular events (mostly, aortic aneurysms in the abdomen). In another follow-up (18), 10-y mortality was 61.8% in males with symptomatic PAD (ABI Ͻ 0.9); in comparison, in males without PAD (ABI Ͻ 0.9) mortality was 16.9%. Mortality rates in females were 33.3% and 11.6%, respectively. Less than 25% of patients with PAD (ABI Ͻ 0.9) survived for 10 y, vascular mortality being the dominant cause of death in that setting. Aft er correction for established risk factors, PAD was an independent predictor of death. In the latter report, the subjects were classifi ed as normal (no evidence of PAD), asymptomatic (no claudication), symptomatic (with claudication), and as subjects with severe PAD (claudication ϩ abnormal diagnostic tests). Th e risk of death was related to the severity of PAD and was as strong as that for cancer. Th e latter has emerged from 744 patients with PAD (19): in a 5-y follow-up, those with severe PAD (ABI Ͻ 0.4) had 56% probability of surviving. Based on data collected in parallel (1986 -1993) , this fi gure was comparable with the 5-y survival curves (52%) in Caucasian patients with non-Hodgkin lymphomas . Th ese data set the stage for an extraordinary high morbidity and mortality in patients with PAD. As a matter of fact, over the last decades, while no currently available specifi c treatment for PAD is associated with a signifi cant reduction in morbidity and mortality rates, screening programs for primary prevention of coronary artery disease and use of statins, ACE and platelet inhibitors, β -blockers, etc. have dramatically decreased the risk of major cardiovascular events (and of progression in arterial occlusion) in the PAD setting (20). Critical limb ischemia (CLI; ABI Ͻ 0.4), is observed in 12% of the PAD population (21). In most cases, CLI is an advanced thrombotic complication of PAD, due to inadequate resting blood fl ow to the lower limbs, and marked by rest pain, ulceration, and eventually gangrene and loss of the limb (22) . Th e limb typically has developed a collateral blood supply, and the fi nal occlusion of the vessel oft en is not immediately limb threatening with slow progression of disease (23). CLI is seldom the result of an acute event (e.g. embolism, thrombosis, or trauma). Approximately 80% of emboli originate in the heart (e.g. left atrial appendage, left ventricular apex, cardiac valves) (24). In the remaining cases, they originate from the aorta or peripheral vessels or from the veins (with migration through patent foramen ovale and atrial septal defects). Patients with CLI are candidates for prompt revascularization. CLI increases mortality: in the fi rst year aft er the diagnosis 25% of patients (45% with amputation) will die, and 30% of them will have amputations, whereas only 45% will survive with both legs. Aft er 5 years more than 60% of patients have died (25).
Literature search method
In an attempt to identify potential reasons why PAD with IC is underdiagnosed and undertreated, the following questions have been raised: 1) Is the overall quality of the evidence concerning diagnostic tools for PAD as good as that for other atherothrombotic conditions? And 2) Is the overall quality of the evidence concerning antithrombotic interventions for PAD as good as that for other atherothrombotic conditions?
To estimate absolute benefi ts, harms, and limitations associated with a given treatment/diagnostic tool, a Medline literature search of the highest-quality published systematic reviews and meta-analyses of randomized controlled trials in the area was performed using the key words ' diagnostic tools AND PAD ' and ' treatments AND PAD ' , and references of relevance were selected manually. Other references were either provided by the authors or obtained from the reference lists within the relevant selected articles. Databases were updated to August 2013.
Non-invasive and invasive tools for the diagnosis of PAD
Non-invasive imaging is mandatory to detect the anatomy, morphology (e.g. subclinical non-obstructive), and characteristics (e.g. instability) of the plaque in PAD.
By combining B-mode ultrasound and color Doppler ultrasound, duplex ultrasound (DUS) identifi es the anatomical location and the degree of a stenosis. Peak systolic velocity (PSV) ratios (as determined within and beyond the obstruction and as compared with the adjacent upstream segment) are useful to estimate the rate of stenosis: a PSV ratio Ͼ 2:1 argues for Ͼ 50% stenosis, a PSV ratio Ͼ 4:1 for a Ͼ 75% stenosis, and a PSV ratio Ͼ 7:1 for a Ͼ 90% stenosis (26). DUS helps identify patients with the need for endoluminal revascularization (27, 28) and is currently employed to follow-up venous graft s (29 -36) . Th e high sensitivity, specifi city, diagnostic accuracy, and cost-eff ectiveness of DUS has been documented (37 -39).
Magnetic resonance angiography (MRA) very carefully defi nes the borders of the arterial wall (40 -42) and identifi es the unstable fi brous cup of an atherosclerotic plaque (43). Moreover, by allowing the identifi cation of size, composition (i.e. the lipid-enriched necrotic core, hemorrhages, calcifi cations, etc.), and ulcerative components, MRA contributes to the morphological characterization of a plaque (44 -46) . Th e morphological characterization of the plaque is improved by gadolinium contrast media that help diff erentiate the necrotic core from the surrounding fi brous tissue (47,48) and document neo-angiogenesis and the infl ammatory burden (49, 50) . Meta-analysis and systematic reviews argue for the diagnostic accuracy of MRA in the PAD setting (51 -53). However, these studies also claim that MRA tends to overestimate the degree of stenosis. Th is is mostly due to turbulence and metal clips that, by mimicking vessel occlusions, can cause artifacts. Likewise, some metal stents may obscure vascular fl ow and, in turn, cause artifacts (54).
Short acquisition time, very thin slices, high spatial resolution, and improved multi-detector computed tomography scanners enable scanning of the entire vascular tree in a limited period of time by computed tomography angiography (CTA), with a low amount of contrast medium employed and radiation burden (55). Th ese recent technical developments have made CTA one of the most important imaging techniques in PAD. A recent metaanalysis (56) showed its high diagnostic accuracy in the PAD setting. Th e pooled sensitivity to detect a Ͼ 50% stenosis or occlusion was 95% (92% -97%) and the pooled specifi city 96% (93% -97%). CTA correctly identifi ed occlusions in 94% of segments, the presence of Ͼ 50% stenosis in 87% of segments, and absence of signifi cant stenosis in 96% of segments. Nevertheless, similarly to MRA, CTA tends to overestimate the degree of stenosis (see above for details) (54).
In spite of the current availability of less invasive imaging techniques, catheter angiography (CA) with or without digital subtraction angiography (DSA) is the gold-standard fi rst-line imaging investigation for patients with PAD and the reference method for guiding percutaneous peripheral interventional procedures (54). However, due to the need for contrast media (that may cause renal toxicity, arterial wall dissection, emboli, fi stulae, pseudoaneurysms, and access site complications) and to its inherent limitations (no careful hemodynamic study of the stenotic segment nor of its length (overestimated) is possible), the clinical use of DSA is currently limited (57).
Indications, limitations, and contraindications of each imaging technique are reported in Tables III and IV. Antithrombotic treatment in asymptomatic and symptomatic PAD
Pharmacology of major antithrombotic agents

Antiplatelet agents in PAD
Following atherosclerotic plaque disruption/endothelial cell detachment, circulating platelets, exposed to a highly thrombogenic environment, become activated (58). A series of soluble agonists (ADP, thromboxane A 2 (T ϫ A 2 ), serotonin (5-HT), and thrombin) recruit and activate additional platelets. Upon activation, glycoprotein (Gp) IIb/IIIa ( α IIb β 3 integrin) mediates platelet aggregation and spreading by means of fi brinogen bridges, which, once converted to fi brin, ultimately contribute to thrombus stabilization. Th is leads to the formation of plateletrich thrombi that, occluding the arterial lumen and impairing blood-fl ow and oxygen supply, cause acute ischemia. Th e effi cacy of aspirin lies in its ability irreversibly to inhibit platelet
Aspirin
Owing to its effi cacy and favorable cost-eff ectiveness, aspirin is the mainstay treatment for all atherothrombotic conditions. A recent meta-analysis (60) has assessed the role of aspirin in primary (95,000 subjects at low cardiovascular risk) and secondary (17,000 patients at medium/high risk) vascular prevention. While in high-risk conditions the advantage of aspirin outweigh the inherent bleeding hazard, in primary prevention aspirin is associated with an absolute benefi t of 0.06%/year, too exiguous when compared to the 0.03% increase in major bleedings.
Ticlopidine
Ticlopidine was the fi rst agent of the thienopyridine class shown both to prevent the interaction of ADP with its platelet purinergic receptor and to cause inhibition of fi brinogen binding to the α IIb β 3 integrin (62). In subjects with a history of cerebrovascular events, ticlopidine was superior to placebo and to aspirin in the reduction of stroke, AMI, or vascular death (63). In addition, the combination of ticlopidine with aspirin was successful in acute coronary COX-1 (by acetylating a serine located near the active site of the enzyme) and, in turn, T ϫ A 2 formation (59). Th e transduction of the ADP signal involves its interaction with two platelet receptors belonging to the P 2 purinergic family, the G α qcoupled receptor P 2 Y 1 and the G α i-coupled receptor P 2 Y 12 (60). Th e concomitant activation of both the G α q and G α i pathways by ADP is needed for platelet aggregation to occur. Signaling from the P 2 Y 1 receptor causes platelet shape change and rapid transient aggregation, whereas the signaling from the P 2 Y 12 receptor facilitates sustained irreversible aggregation and stimulates surface expression of the pro-infl ammatory P-selectin. In addition, the P 2 Y 12 receptor plays a critical role in the amplifi cation of platelet aggregation induced by agents other than ADP, including 5-HT, T ϫ A 2 , and thrombin. Together, these contribute to thrombus growth and stability. Two main classes of antiplatelet agents are licensed and widely used chronically in PAD: acetyl salicylic acid (aspirin) and P 2 Y 12 inhibitors (ticlopidine, clopidogrel, prasugrel, cangrelor, ticagrelor) (61). , and 12 months, and then yearly aft er graft placement for PAD and for CLI. b Recommended for evaluation of patients when revascularization is contemplated. c To optimize decisions on the access site, and to minimize contrast dose and catheter manipulation. d As other non-invasive imaging modalities including MRA, CTA, and color fl ow duplex imaging, to be used in advance of invasive imaging procedures. e Patients with baseline renal insuffi ciency should receive hydration before undergoing CTA (Grade A, level 2b). f A documented history of contrast reaction before the performance of contrast angiography implies that an appropriate pre-treatment should be administered before contrast is given (Class 1; level B). When conducting a diagnostic lower-extremity arteriogram in which the signifi cance of an obstructive lesion is ambiguous, trans-stenotic pressure gradients and supplementary angulated views should be obtained (Class 1; level B); hydration is needed before undergoing contrast angiography in patients with baseline renal insuffi ciency (Class 1; level B); treatment with n-acetylcysteine in advance of contrast angiography is suggested for patients with baseline renal insuffi ciency (creatinine Ͼ 2.0 mg per dL) (Class 2a; level B); follow-up clinical evaluation, including a physical examination and measurement of renal function is recommended within 2 weeks aft er contrast angiography to detect potential delayed adverse eff ects, such as atheroembolism, deterioration in renal function, or access site injury (e.g. pseudoaneurysm or arteriovenous fi stula) (Class 1; level C). CV-DUS ϭ continuous wave Doppler ultrasound; PTA ϭ percutaneous trans-luminal angioplasty.
syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with stent implantation (64). Diarrhea, aplastic anemia, thrombotic thrombocytopenic purpura, and neutropenia are the main limitations for a widespread use of ticlopidine.
Clopidogrel
Th e thienopyridine prodrug clopidogrel irreversibly binds the P 2 Y 12 platelet receptor aft er a two-step activation by cytochrome P450 (CYP) liver isoenzymes. A variety of polymorphisms in the CYP2C19 gene (most oft en the CYP2C19 * 2), associated with a 20% -25% production of inactive metabolite, diminish the response to clopidogrel. Among subjects under treatment with clopidogrel for a previous vascular event, carriers of these polymorphisms have a 50% higher risk of cardiovascular death, AMI, or stroke (58). Among clopidogrel-treated patients, carriers of at least one allele associated with the loss of or a reduced function in the CYP2C19 gene had a higher than normal occurrence of fatal and non-fatal coronary thrombotic events, as well as of stent thrombosis (58). In the same study population, polymorphic alleles of a gene modulating clopidogrel absorption (ABCB1) have been associated with a higher rate of cardiovascular events at 1-year follow-up as compared to wild-type subjects.
Ticagrelor
Ticagrelor, an orally active cyclopentyl-triazolo-pyrimidine, binds to domains of the P 2 Y 12 receptor other than those recognized by ADP (the 1, 2, and 7 transmembrane domains, the extracellular loop 2, and the N-terminal domain), determining a potent and rapid non-persistent receptor conformational change. Aft er the occupancy of P 2 Y 12 , ADP-catalyzed conversion of cAMP from ATP, dephosphorylation of phosphorylated VASP, and activation of phosphoinositide 3-kinase are blocked. Th e net result is a reduced exposure of fi brinogenbinding sites on the α IIb β 3 integrin receptor and, in turn, the inhibition of platelet aggregation. Inhibition of ADP-mediated constriction of vascular smooth muscle and enhancement of adenosine-induced coronary blood-fl ow are also reported. Aft er oral administration, ticagrelor is rapidly absorbed and does not require hepatic biotransformation to be pharmacologically active. However, ticagrelor is also metabolized to an equipotent, active metabolite (AR-C124910XX) by CYP 3 A 4 enzymes. As both ticagrelor and AR-C124910XX are excreted by the intestinal route, no dose adjustment is needed in kidney failure. On the other hand, the concomitant use of CYP 3 A 4 inhibitors/inducers as well as a signifi cant liver dysfunction may be of concern for its use. Aft er pharmacodynamic evaluations (65,66), a 90-mg twice-daily dose of ticagrelor has been chosen to optimize its effi cacy, safety, and tolerability. A loading dose of 180 -270 mg may minimize intersubject variability as to initial inhibition in platelet aggregation and may be appropriate in ticagrelor-naive patients with ACS or in preparation for PCI. In 174 subjects with a recent coronary artery disease receiving 75 -100 mg/day aspirin (92 also under ticagrelor 180-mg load and 90 mg twice-daily maintenance dose, and 82 also under clopidogrel 600-mg load and 75 mg/d maintenance dose) the genotyping of the cytochrome P450 (CYP) 2C19 ( * 1, * 2, * 3, * 4, * 5, * 6, * 7, * 8, * 17) was performed. In addition, platelet function was measured (by aggregometry, VerifyNow P 2 Y 12 assay, and VASP assay at pre-dose, 8 hours post-loading, and during maintenance). Th ere was no signifi cant eff ect of the genotype on platelet function during aspirin therapy alone. On the other hand, irrespective of the 2C19 genotype, of the metabolizer status, and of the assays employed, subjects on ticagrelor showed a lower platelet reactivity than did those on clopidogrel ( P Ͻ 0.01). Th is is consistent with a genotypeindependent better pharmacodynamic eff ect of ticagrelor as compared to clopidogrel (67). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64   65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128 6 G. and improves the clinical outcome of percutaneous revascularization (91). To this end, the reduction of the A1c hemoglobin levels Ͻ 7% should be associated with the control of all risk factors, proper foot care (e.g. cleansing of skin lesions), and appropriate footwear (92).
Secondary prevention of cardiovascular events in symptomatic PAD
Main fi ndings from the meta-analysis of aspirin therapy for primary and secondary prevention of coronary artery disease (60) also show that, in a population at high risk for a serious vascular event (i.e. 8.2%/ year), the risk/benefi t ratio between bleedings and prevention of total mortality, non-fatal MI, and non-fatal stroke is in favor of the prolonged use of aspirin. Clopidogrel, when administered alone in about 20,000 patients (all with a history of AMI, stroke, or PAD) in the randomized CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk for Ischemic Events) (93) , was only marginally superior to aspirin (relative risk reduction (RRR) 8.7; P ϭ 0.043) in preventing non-fatal AMI and non-fatal extracranial bleeding with little or no eff ect on total mortality. Th is was the overall outcome in patients with a recent stroke and in patients with a recent AMI. However, when the chronic ' PAD subset ' was analyzed alone (over 8000 patients), a 24% risk reduction in major adverse ischemic events was found.
Th is was a pre-specifi ed (pre-randomization) stratifi cation, and the validity of such a conclusion in PAD patients led to the positive study outcome and FDA approval. A signifi cantly high effi cacy of clopidogrel has also been shown when this drug was employed for the ' dual antiplatelet therapy ' . Th e CURE (94) and the CREDO (95) studies established the superiority of clopidogrel in combination with aspirin versus aspirin alone in ACS and in ACS with PCI, respectively. In high vascular risk patients with atherothrombosis (manifested as a recent stroke, recent MI, or symptomatic PAD), a meta-analysis of 10 studies examining the eff ects of thienopyridines (clopidogrel and ticlopidine) versus aspirin achieved results similar to those of the CAPRIE trial (96). A reduction in non-fatal stroke and an increase in non-fatal extracranial bleeding with no eff ect on total mortality or non-fatal AMI was found in the long-term effi cacy of clopidogrel ϩ aspirin versus aspirin alone in the randomized Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial (97). A Cochrane systematic review that evaluated short-and longterm dual antiplatelet therapy in patients with established coronary artery disease reached similar conclusions (98). Finally, in a metaanalysis of three studies there was no eff ect on mortality, non-fatal AMI, or non-fatal stroke, and a signifi cant raise in major bleeding events in patients receiving warfarin (PT-INR 2-3) ϩ aspirin versus aspirin alone (73).
Cilostazol, pentoxifylline, and prostanoids are used to improve the quality of life in patients with symptomatic PAD and with claudication. Since claudication itself is responsive to smoking cessation and exercise therapy, drugs for improving the quality of life should be considered only in patients who have limitations aft er smoking cessation and exercise therapy. Two systematic reviews have shown that patients with symptomatic PAD receiving cilostazol are more likely to experience important benefi ts as to physical health sub-scale (but not to health-related quality of life) than those receiving placebo (99,100) or pentoxifylline (101). No diff erence in rates of AMI, stroke, or death was found in another review on 1374 participants randomized to cilostazol and 973 randomized to placebo (102). Nor has a signifi cant eff ect of cilostazol on major or minor bleeding rates been detected in another systematic review (103).
Cilostazol
Cilostazol, selectively targeting phosphodiesterase type 3 (PDE3) and, then, determining intracellular cAMP accumulation, inhibits platelet aggregation (68). In diabetic patients on standard dual antiplatelet therapy, adjunctive treatment with cilostazol enhances inhibition of platelet P 2 Y 12 signaling (69). A Cochrane review (70), in which two randomized studies on stroke prevention were summarized, documented that, compared with aspirin, cilostazol was associated with a signifi cantly lower risk of vascular events (6.77% versus 9.39%; RR 0.72; 95% CI 0.57 -0.91, composite outcome) and a lower risk of hemorrhagic stroke (0.53% versus 2.01%; RR 0.26; 95% CI 0.13 -0.55). In terms of outcome of safety, cilostazol was associated with signifi cantly fewer adverse events (8.22% versus 4.95%; RR 1.66; 95% CI 1.51 -1.83) than aspirin. In the SILOAM phase IV study (ClinicalTrials.gov Identifi er: NCT01261832), a triple antiplatelet therapy (cilostazol plus aspirin and clopidogrel) is compared (at 1 month and at 6 months) with the standard dual antiplatelet treatment (ASA and clopidogrel) in 951 ACS subjects (expected number) undergoing PCI and drug-eluting stent implantation. Th e primary effi cacy end-point is the occurrence of major cardiovascular and cerebrovascular events (total death, non-fatal myocardial infarction, repeat revascularization, stroke). Th e end of the study is expected by July 2014.
Primary prevention of cardiovascular events in asymptomatic PAD (Table V)
On the basis of an individual participant data meta-analysis for primary and secondary prevention of coronary artery disease (60) and of data from a meta-analysis on cancer (71), aspirin is expected to reduce total mortality and to increase major bleedings (72). Since this is especially true in subjects taking more than one drug daily (most PAD patients), and since similar benefi ts are seen in patients with IC and those who had undergone peripheral vascular graft ing or angioplasty, the use of aspirin over a prolonged time period should be encouraged on an individual basis. Regardless of this decision, intensive treatment for cardiovascular risk factor modifi cations (73) is mandatory for primary prevention of cardiovascular events in patients with PAD. Tobacco cessation should be encouraged, eventually by behavior modifi cation or pharmacologic strategies (74). Cessation of tobacco use signifi cantly reduces lower-extremity symptoms and progression of PAD, thus helping improve the maximal walking distance achieved by structured exercise programs (75). As in other patients with high cardiovascular risk, LDL cholesterol levels should be lowered to Ͻ 70 mg/dL in PAD patients (76). A sub-analysis of 6748 patients with PAD in the Heart Protection Study showed signifi cant reductions in total mortality, vascular mortality, coronary heart disease events, strokes, and non-coronary revascularization in those treated with simvastatin (77). Th ere was no threshold cholesterol value below which statin therapy was not associated with benefi t (78 -80). Statins improve the pain-free walking distance (81) and reduce the progression of PAD, the overall cardiovascular risk, and the occurrence of complications needing invasive procedures (82). Th e goal for blood pressure control in PAD is Ͻ 140/90 mmHg; in those with PAD and DM or with chronic kidney disease, it should be Ͻ 130/80 mmHg (83). In a subgroup of 4046 patients with PAD, the Heart Outcomes Prevention Evaluation study showed that those randomly assigned to the angiotensin-converting enzyme inhibitor ramipril had a 22% reduction in risk, compared with the placebo group, that was independent of lowering of blood pressure (84). Because of the additional cardio-protective eff ects, the use of β -blockers is important in patients with coexisting coronary artery disease. Although no trials have been designed or powered to examine glycemic control, a tight plasma glucose control reduces PAD progression in diabetic (pelvic or lower extremity), in 179 patients complicated by extensive dissection to i.v. unfractionated heparin vs subcutaneous nadroparin was administered for 1 week post-procedure (followed by 6 months of aspirin in each arm). Nadroparin was associated with a reduction in vessel restenosis/occlusion at 6 months (OR 0.35; 95% CI 0.19 -0.65) but not in the amputation rate (OR 1.0; 95% CI 0.20 -5.10). However, the overall quality of the evidence is low due to risk of bias, imprecision, and indirectness. Th us, aspirin or clopidogrel should be preferred as in symptomatic PAD. In patients undergoing PTA with stent placement, the practice of a loading dose of clopidogrel in addition to aspirin pre-procedure and then continuing dual antiplatelet therapy for 1 -3 months post-PTA, particularly if a stent is placed in a small peripheral vessel, is based on the results from coronary artery stenting trials. However, dual antiplatelet therapy is associated with a high risk of major bleeding compared with single antiplatelet therapy. Th us, aspirin or clopidogrel alone should be preferred In one study of that Cochrane Systematic Review, compared with placebo, aspirin plus dipyridamole for 12 months was associated with a reduction in amputations rates (34 fewer amputations per 1000 patients treated (51 fewer to one more)) Pooled data from three studies of that review suggested that treatment with aspirin plus dipyridamole was associated with a possible reduction in non-fatal AMI but not in non-fatal stroke. However, aspirin plus dipyridamole was associated with an increase in bleeding (eight more major bleeding events per 1000 treated (one fewer to 30 more)). However, the overall quality of the evidence is low due to risk of bias, imprecision, and indirectness. Th us, aspirin or clopidogrel alone should be preferred
Below-knee bypass graft surgery with prosthetic graft s f Dual antiplatelet treatment to be avoided for the inherent bleeding risk.
Other studies failed to demonstrate or exclude an eff ect of aspirin and dipyridamole vs warfarin in reocclusion at 6 months following PTA or an eff ect on 12-month reocclusion in patients taking ticlopidine compared with warfarin.
g Urokinase bolus or t-PA 100 mg bolus. Compared to surgery, thrombolysis has a signifi cantly higher 30-d risk of bleeding and stroke. Initially, streptokinase was the most widely used agent, but because of safety concerns (e.g. allergic reactions), it has largely been replaced by urokinase and rt-PA.
h Long-term aspirin d or clopidogrel e to be added for prevention of vascular events. benefi t of catheter-directed thrombolysis in terms of reducing amputation and improving amputation-free survival up to 1 year. Th ese results were not reproduced in commercially written and performed studies. In the past, thrombolysis for acute limb ischemia was administered i.v.; this strategy has been now replaced by catheterdirected thrombolysis. In a Cochrane systematic review on the management of acute lower-limb ischemia (109), compared to thrombolysis by recombinant tissue-type plasminogen activator (rt-PA) or urokinase, i.v. streptokinase was associated with a high rate of amputation at 30 days (7/20 versus 1/20; RR 7.0; 95% CI 0.95 -51.80) and no eff ect on limb salvage, major hemorrhage, or death. (Table VI) When antiplatelet drugs and the control of DM, of dyslipidemia, of cigarette smoking, and of hypertension are not suffi cient in the treatment of CLI, surgery (110) or percutaneous transluminal angioplasty (PTA) with or without stenting (111) are needed. Th e objective of revascularization is to establish adequate infl ow to the distal vessels. Balloon devices are used to this end, either in the contralateral retrograde common femoral artery (CFA) access or in the ipsilateral anterograde CFA access. Th is intervention is aimed at establishing straight line fl ow in at least one tibial vessel, to supply the area of the foot with rest ischemia (typically, the forefoot) or with tissue loss. Th is treatment shows a very high immediate limb salvage rates ( Ͼ 90%), with Ͻ 2% intervention-related mortality and Ͻ 5% risk of complications. In the fi rst 12 -24 months, the limb salvage rates are above 80%, and, when the therapeutic goal is achieved, the patency of treated arteries leads to resolution of ischemic lesions. Th e effi cacy of angioplasty has been confi rmed by several studies (112, 113) . A recent meta-analysis has shown that the effi cacy and safety of endovascular techniques are comparable to surgical interventions (114). By releasing anti-proliferative drugs such as paclitaxel, drug-eluting balloons effi ciently maintain arterial patency aft er PTA and reduce the risk of restenosis (115 -117). A possible side eff ect of this procedure is wall dissection and restenosis. Th e use of stents is thought to reduce such risk (118 -120). HowIn a meta-analysis (seven randomized studies) (104), 643 patients were analyzed as to the use of prostaglandin E 1 (PGE 1 ) in the treatment of advanced PAD. At the end of treatment, PGE 1 showed a signifi cantly better response (ulcer healing and/or pain reduction) as compared to placebo (47.8% for PGE 1 versus 25.2% for placebo, P ϭ 0.0294). Aft er a 6-month follow-up, a slight although still signifi cant diff erence in favor of PGE 1 was seen for the combined end-point ' major amputation or death ' (22.6% for PGE 1 versus 36.2% for placebo, P ϭ 0.0150). Th at the benefi t of PGE 1 is apparent in the short term but decreases over time had been previously reported in a multicenter trial on 1560 patients with chronic critical leg ischemia (105). Th e response rate (ulcer healing and/or pain relief) of the pooled treatment groups was 60.2% for PGE 1 , 25.2% for placebo, and 53.6% for iloprost, in that report. Th e adverse events rate of the pooled treatment groups showed a good tolerability for PGE 1 with a rate of 39.6% in comparison to 73.9% for iloprost and 15.4% for placebo. In a recent Cochrane systematic review on 13 studies (106), Ͼ 75% of subjects with critical limb ischemia without chance of rescue or reconstructive intervention that received prostanoids experienced at least one drug-related adverse event (i.e. headache, nausea, vomiting, diarrhea, and facial fl ushing) in addition to improved rest for pain and ulcer healing.
Surgical revascularization in patients with CLI
By preventing clot propagation and further embolism, shortterm anticoagulation treatment is routinely used to reduce the extent of ischemia in acute limb ischemia. Th ere are no formal studies demonstrating improved outcomes with such strategy. To restore fl ow to the occluded artery, either surgery or catheterdirected intra-arterial thrombolysis is employed. Th ere are no data to support reperfusion therapy over anticoagulation alone in this setting. In a meta-analysis (107) that has compared benefi ts and harms of intra-arterial thrombolysis versus surgery, only the risk of stroke and of major bleeding at 30 days was higher for thrombolysis as compared with surgery, no eff ect being found on amputation, death, or limb salvage.
However, we believe that caution is needed when commenting this conclusion. Among those analyzed, the only randomized comparative study which was designed and performed by investigators was the STILE trial (108). In patients with true acute limb ischemia (1 -14 days) the study reported a signifi cant patients undergoing unilateral below-knee bypass graft surgery for PAD to clopidogrel ϩ aspirin versus placebo ϩ aspirin (131). Th ere was a signifi cant decrease in amputations in patients treated with clopidogrel ϩ aspirin, but only in the subgroup of patients undergoing prosthetic graft bypass. Finally, together with a reduction in non-fatal AMI and a signifi cant increase in extracranial major bleedings, there was no advantage over aspirin of a high-intensity oral anticoagulation (target PT-INR 3-4.5) on all-cause mortality and non-fatal stroke in patients who had undergone infrainguinal bypass graft ing (132).
Open issues and areas of research
Due to imprecision, indirectness, and risk of bias, the overall quality of the evidence summarized above is low in most cases, and open issues and areas of research emerge. Because of the paucity of studies regarding type and duration of antithrombotic therapy, in patients undergoing PTA with stent placement, the rationale for the current practice (aspirin and loading dose of clopidogrel pre-procedure; dual antiplatelet therapy for 1 -3 months thereaft er, particularly if a stent is placed in a small peripheral vessel) is largely based on indirect evidence from data in patients undergoing coronary stenting trials (133). However, the risk of stent thrombosis is conceivably lower in stenting larger-caliber peripheral arteries than in smaller coronary arteries. Diff erences in stent types and diff ering outcomes should be also considered in PAD.
A meta-analysis (134) has shown that, compared with those showing an optimal response to the drug, patients with persistent platelet reactivity despite clopidogrel treatment ( ∼ 30% of total) have a signifi cantly higher risk of death and/or ischemic recurrence (58). Th e same risk has been reported for aspirin ( ' aspirin resistance ' ) (135). Th e possibility has been documented that genetic variations in gut/liver enzymes that control biotransformation (and in turn the pharmacological activity) play a role in the low response to clopidogrel (136). Aft er oral administration, ticagrelor is rapidly absorbed and does not require hepatic biotransformation to be pharmacologically active. Compared to clopidogrel, a 16% RRR in major adverse cardiovascular events following acute coronary syndrome, a 21% RRR in cardiovascular mortality, and a numerical 22% RRR in all-cause mortality has been documented in 18,000 NSTEMI or STEMI patients in the multicenter, randomized, double-blind, double-dummy phase III PLATO trial (ticagrelor 90 mg b.i.d. versus clopidogrel 75 mg/d) (137). In ∼ 11,500 male and female patients ( Ͼ 50 years of age) with established PAD, the EUCLID (Examining Use of tiCagreLor In paD) study protocol (ClinicalTrials.gov Identifi er: NCT01732822) is now comparing 90 mg b.i.d. oral ticagrelor with 75 mg/d oral clopidogrel and the corresponding placebo on the risk of cardiovascular death, AMI, ischemic stroke, and TIMI major (primary safety objective) and major or minor bleeding events. October 2015 is the estimated primary completion date for the EUCLID study protocol.
By preventing clot propagation and further embolism, short-term anticoagulation treatment with therapeutic doses of heparin is commonly used to reduce the extent of ischemic injury in the management of acute limb ischemia. No formal studies demonstrating improved outcomes with anticoagulation (nor side eff ects of heparin versus other anticoagulant agents) are available. Although eff ective, vitamin K antagonists have numerous limitations, which complicate their use. Th ese limitations have prompted the introduction of new oral anticoagulants that overcome many of the problems associated with vitamin K antagonists. Th e new oral direct oral ever, presently it is unclear whether PTA with stent placement is superior to PTA alone with respect to patient-important outcomes. Compared with PTA without routine stenting, PTA plus routine stenting for superfi cial femoropopliteal arterial disease was associated with a reduction in restenosis (RR 0.85; 95% CI 0.69 -1.06) but with no eff ect on the need for target vessel revascularization (RR 0.98; 95% CI 0.78 -1.23) (121). Among strategies regarding surgical revascularization and endovascular revascularization, great attention is currently paid to benefi ts of drug-eluting stents. In the prospective, multinational randomized controlled Zilver PTX trial, the 2-year safety and effi cacy of a paclitaxel-coated drug-eluting stent (DES) was compared with PTA in patients with superfi cial femoral artery lesions. In patients who received the paclitaxelcoated DES, 2-year outcomes showed statistically signifi cant diff erences in terms of event-free survival, primary patency, and clinical benefi ts (122).
Th e TASC-II classifi cation of ischemic lesions is used to decide between PTA or surgical interventions -TASC A and B lesions being best treated with PTA, TASC C and D lesions being usually treated with surgical strategies. Th e prosthetic material used is dacron or ePTFE, autologous materials (e.g. femoral veins or cryoconserved allogenic veins or arteries) being used in cases with infections of the original graft (123,124). Aft er 5 years, the primary patency rate of all surgical procedures is Ͼ 80%, signifi cant diff erences being found when comparing claudicants with patients with CLI (125). Such rates of success progressively decrease in patients with local co-morbidities. In a retrospective review (126), there was a signifi cant diff erence in primary patency aft er 36 months (better for surgery). However, it was severely diminished in patients with diabetes and distal PAD, and, compared with patients undergoing PTA, surgical patients needed more oft en additional interventions of reconstruction. Debulking procedures are taken into account in selected patients (i.e. those at a high risk of PTArelated complications) (127). Th ey include the excimer laser (to perform photoablation of occlusive material), the Rotablator (for the treatment of calcifi ed plaques), and new techniques such as the Silverhawk system (designed for eccentric and not severely calcifi ed infrainguinal lesions), the Rochawk system (for calcifi ed plaques), and the newer Jetstream system (with an aspiration device to perform simultaneous thrombectomy and atherectomy).
Antithrombotic treatments in patients undergoing revascularization procedures (Table V) A Cochrane review (128) on patients undergoing lower-extremity PTA without stent placement reported a reduction in reocclusion in patients taking aspirin ϩ dipyridamole compared with placebo. Another study randomized patients to i.v. unfractionated heparin versus subcutaneous nadroparin administered for 1 week postprocedure (129). Nadroparin was associated with a reduction in the rate of vessel restenosis/occlusion but not in amputation. However, the overall quality of the evidence in these studies is low. Similarly poor is the evidence from studies on antithrombotic treatments in patients undergoing PTA with stent placement.
In a Cochrane systematic review in patients receiving post-infrainguinal bypass graft surgery compared to placebo, aspirin ϩ dipyridamole resulted in fewer graft occlusions (130). In one study of that systematic review, compared with placebo, aspirin ϩ dipyridamole was associated with a reduction in amputations rates. Also in this case, the overall quality of the evidence is low. Th us, aspirin or clopidogrel are suggested as the treatment of choice in symptomatic PAD.
Th e Clopidogrel and Acetylsalicyclate Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) study randomized salvage. Antiplatelet drugs caused resolution of CLI and decreased the amputation rate by about one-third, while the advantage of the test treatment with alprostadil-α -cyclodextrine was confi ned to CLI resolution only. Together, these data provide the rationale for defi ning stratifi cation criteria for a severity score to estimate reliably the achievable benefi t in routine practice and/or identify PAD subjects at the highest risk of amputation/vascular death.
By allowing the identifi cation of size and ulcerative components and by diff erentiating the necrotic core from the surrounding fi brous tissue, neo-angiogenesis, and the infl ammatory burden composition, MRA contributes to the morphological characterization of a plaque (see above). Whether and the extent to which early and more aggressive strategies in PAD patients at the highest risk of ischemic events should be based, at least in part, on non-invasive and invasive tools for the diagnosis of PAD is poorly understood.
Innovative treatments with growth factors or blood progenitor transfer (160) are under evaluation to reduce pain and the rate of amputation in patients who have severe PAD and do not respond to PTA or surgery (e.g. those with DM) (161). In addition to the obvious pathophysiological and therapeutic implications, information from these model systems should help clarify whether conditions (e.g. CLI) other than an acute coronary syndrome argue for a ' pan-vascular destabilization ' status (162).
anticoagulants (DOACs) fall into two main classes: direct thrombin inhibitors (factor IIa inhibitors, dabigatran etexilate) and direct FXa inhibitors (rivaroxaban, apixaban, edoxaban) (138). Although agents in the two classes have distinct mechanisms of action, targeting distinct enzymes in the coagulation pathway, all of the new drugs attenuate fi brin formation and have features in common that distinguish them from vitamin K antagonists, such as warfarin. Th ese common features include a rapid onset of action, few drug -drug interactions, and a predictable anticoagulant response that enables fi xed dosing for several indications and across a diverse range of patients with no need for routine coagulation monitoring. Major issues concerning the pharmacology including the effi cacy/safety of DOACs in clinical trials on prevention and treatment of thromboembolism (in medical and surgical patients), as well as in AF have been recently reviewed (139). Moreover, in a 14-mo follow-up in the everyday practice, 3.5 gastrointestinal bleedings and 2.4 intracranial hemorrhages/100,000 days at risk occurred in new users of warfarin, compared to 1.6 gastrointestinal bleedings and 0.8 intracranial hemorrhages/100,000 days at risk among new users of the DOAC dabigatran (140). A randomized trial of DOACs versus low-molecular-weight heparin in ALI should be considered.
Claudication unresponsive to physical exercise and smoking cessation is present in a relevant group of patients with IC. Data argue for this phenotype as identifying those with a heritable predisposition to more severe vascular events (i.e. with unfavorable combination(s) of genes modulating lipid metabolism, arterial pressure, vascular function, infl ammation, hemostasis, and/or leukocytes and endothelial cell function) (141 -144). Th is issue deserves to be thoroughly addressed.
Reports call attention to the occurrence of PAD in patients with AF (145) or with chronic renal failure (CRF) (146), a higher than normal risk of ischemic events and mortality being documented in both these settings (147 -149) . Th e prevalence of PAD is higher in patients with DM than in the general population (150 -152); a distal location with an involvement of the infrapopliteal vessels is more common in DM (153, 154) , and the severity and outcome of PAD is worse in DM and is strongly related to duration and severity of the metabolic disorder (155 -157). In a meta-analysis of ∼ 48,000 healthy men and women, an ABI Ͻ 0.90 at baseline was associated with an approximate doubling of the 10-year mortality, cardiovascular mortality, and major coronary event rate aft er adjusting for the Framingham risk score (158). When evaluating patients for primary prevention with aspirin, it has been suggested (81) to use a risk stratifi cation tool (e.g. the Framingham risk score) which provides estimates of low ( Ͻ 10%), moderate (10% -20%), and high risk ( Ͼ 20%) of cardiovascular events over 10 years, doubling the patient ' s risk score (from a low to moderate or a moderate to high category) when his/her ABI is Ͻ 0.90. Whether this is the case is unknown so far, and deserves to be addressed.
In the ICAI (Ischemia Critica degli Arti Inferiori) trial (159), of 1560 patients enrolled, 298 died within 1 year, 187 were amputees at 6 months, and 746 continued to suff er from CLI. Prior major vascular events doubled the risk of dying within 1 year. Previous revascularization was associated with a lower mortality and a higher probability of amputation. Among cardiovascular risk factors, diabetes increased mortality and lowered the probability of recovery from CLI. Patients with tissue loss had a higher amputation rate and less probability of recovery. Ankle pressure was predictive of mortality and amputation only when it was not measurable. Compared to those in whom surgery was deemed unnecessary, patients requiring revascularization had better chances of recovering from CLI, but not of longer-term survival or limb 3 4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
